MNKD Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals has a net margin of 16.48% compared to MannKind's net margin of -49.65%. MannKind's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

MannKind has a consensus price target of $9.80, signalling upside risk potential of 60.92%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $7.30 which suggests that it could grow by 434.43%. Given that NovaBay Pharmaceuticals has higher upside potential than MannKind, analysts believe NovaBay Pharmaceuticals is more attractive than MannKind.

MannKind has a beta of 1.289, which suggesting that the stock is 28.87% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.646, suggesting its less volatile than the S&P 500 by 35.372%.

MannKind has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MannKind pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

MannKind quarterly revenues are $70.1M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. MannKind's net income of $11.6M is higher than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, MannKind's price-to-earnings ratio is 76.13x while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MannKind is 6.57x versus 0.07x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of 16.48% compared to MannKind's net margin of -2357.27%. MannKind's return on equity of -- beat Palatin Technologies's return on equity of --.

MannKind has a consensus price target of $9.80, signalling upside risk potential of 60.92%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1404.43%. Given that Palatin Technologies has higher upside potential than MannKind, analysts believe Palatin Technologies is more attractive than MannKind.

MannKind has a beta of 1.289, which suggesting that the stock is 28.87% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.929%.

MannKind has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MannKind pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

MannKind quarterly revenues are $70.1M, which are larger than Palatin Technologies quarterly revenues of $350K. MannKind's net income of $11.6M is higher than Palatin Technologies's net income of -$7.8M. Notably, MannKind's price-to-earnings ratio is 76.13x while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MannKind is 6.57x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Rhythm Pharmaceuticals has a net margin of 16.48% compared to MannKind's net margin of -131.25%. MannKind's return on equity of -- beat Rhythm Pharmaceuticals's return on equity of -208.96%.

MannKind has a consensus price target of $9.80, signalling upside risk potential of 60.92%. On the other hand Rhythm Pharmaceuticals has an analysts' consensus of $73.18 which suggests that it could grow by 30.29%. Given that MannKind has higher upside potential than Rhythm Pharmaceuticals, analysts believe MannKind is more attractive than Rhythm Pharmaceuticals.

MannKind has a beta of 1.289, which suggesting that the stock is 28.87% more volatile than S&P 500. In comparison Rhythm Pharmaceuticals has a beta of 2.165, suggesting its more volatile than the S&P 500 by 116.542%.

MannKind has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rhythm Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MannKind pays -- of its earnings as a dividend. Rhythm Pharmaceuticals pays out -- of its earnings as a dividend.

MannKind quarterly revenues are $70.1M, which are larger than Rhythm Pharmaceuticals quarterly revenues of $33.3M. MannKind's net income of $11.6M is higher than Rhythm Pharmaceuticals's net income of -$43.6M. Notably, MannKind's price-to-earnings ratio is 76.13x while Rhythm Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MannKind is 6.57x versus 30.15x for Rhythm Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of 16.48% compared to MannKind's net margin of --. MannKind's return on equity of -- beat Theriva Biologics's return on equity of --.

MannKind has a consensus price target of $9.80, signalling upside risk potential of 60.92%. On the other hand Theriva Biologics has an analysts' consensus of -- which suggests that it could grow by 6141.38%. Given that Theriva Biologics has higher upside potential than MannKind, analysts believe Theriva Biologics is more attractive than MannKind.

MannKind has a beta of 1.289, which suggesting that the stock is 28.87% more volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.234, suggesting its more volatile than the S&P 500 by 23.367%.

MannKind has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MannKind pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

MannKind quarterly revenues are $70.1M, which are larger than Theriva Biologics quarterly revenues of --. MannKind's net income of $11.6M is higher than Theriva Biologics's net income of -$7.7M. Notably, MannKind's price-to-earnings ratio is 76.13x while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MannKind is 6.57x versus 1.59x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.